^
Association details:
| Biomarker: | MAP2K2 C125S |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
As with the homologous and previously-reported MEK1C121S resistance mutation7, MEK2C125S conferred profound resistance to both RAF and MEK inhibition, with fold change in GI50 (half-maximal inhibitor concentration) greater than 100.
DOI:
10.1158/2159-8290.CD-13-0617
